Michael Wilkinson, MD
Cardiovascular Disease · San Diego, CANPI 1699063701
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 47.1% of the total. 2025 is the largest year on record at $56,616, 5.7 times the $9,851 reported in 2019. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $728.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$68K
- Novartis$41K
- Amarin Pharma, Inc.$11K
- Boehringer Ingelheim$9K
- Ionis Pharmaceuticals, Inc.$6K
- Regeneron$4K
- plus $5K from 17 others
Across 39 payments — averaging $51,175 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$826K
- Novartis$624K
- Amgen$545K
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$58,33340%
- Speaking & faculty fees$70,54549%
- Travel & lodging$9,7827%
- Food & beverage$5,9194%
- Education$3280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 89 | $68,257 |
| Novartis | 27 | $40,570 |
| Amarin Pharma, Inc. | 12 | $11,291 |
| Boehringer Ingelheim | 1 | $9,452 |
| Ionis Pharmaceuticals, Inc. | 6 | $5,793 |
| Regeneron | 11 | $4,358 |
| Kaneka Medical America LLC | 1 | $2,304 |
| Amgen | 12 | $859 |
| Esperion Therapeutics, Inc. | 9 | $508 |
| Novo Nordisk | 3 | $290 |
| Impulse Dynamics (USA) Inc. | 2 | $286 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $156 |
| Cleerly, Inc. | 1 | $156 |
| Philips North America LLC | 1 | $150 |
| Medical Device Business Services, Inc. | 1 | $137 |
| Integra Lifesciences Corporation | 1 | $132 |
| Merck | 2 | $73 |
| Merit Medical Systems Inc | 1 | $53 |
| Averitas Pharma Inc. | 1 | $25 |
| Elekta, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
| Pfizer | 1 | $13 |
| Travere Therapeutics, Inc. | 13 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVKEEZA$62,858
- LEQVIO$21,441
- Vascepa$11,131
- JARDIANCE$9,452
- OLEZARSEN$4,913
- TRYNGOLZA$655
- OPTIMIZER$571
- INTEGRA$395
- Repatha$261
- NEXLETOL$221
- PRALUENT$218
- Cleerly Ischemia$156
- Cleerly Labs$156
- (3126) ECC Solutions$150
- INTEGRA DERMAL REGENERATION TEMPLATE$132
- PRIMATRIX$132
- ENTRESTO$119
- Ozempic$114
How this compares
$144,907 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 220 | $174,806 |
| EliquisApixaban | 99 | $112,232 |
| JardianceEmpagliflozin | 72 | $103,125 |
| Praluent PenAlirocumab | 112 | $77,350 |
| Repatha PushtronexEvolocumab | 43 | $38,253 |
| NexletolBempedoic Acid | 43 | $35,784 |
| VascepaIcosapent Ethyl | 68 | $32,997 |
| OzempicSemaglutide | 30 | $30,411 |
| NexlizetBempedoic Acid/Ezetimibe | 34 | $27,169 |
| MounjaroTirzepatide | 21 | $25,222 |
| EntrestoSacubitril/Valsartan | 23 | $24,775 |
| XareltoRivaroxaban | 15 | $22,375 |
| WegovySemaglutide | 12 | $20,806 |
| Ezetimibe | 345 | $13,285 |
| Icosapent Ethyl | 20 | $7,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $112,23299 claims |
| Boehringer IngelheimJardiance | $9,452 | $103,12572 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $508 | $62,95377 claims |
| Novo NordiskOzempic, Wegovy | $290 | $51,21742 claims |
| NovartisEntresto | $40,570 | $24,77523 claims |
| Johnson & JohnsonXarelto | $15 | $22,37515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$278K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.